Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers. Its 363 retail centers comprise approximately 64 million square feet of prime retail space in established trade areas. The Company strives to own and operate shopping centers that reflect Brixmor's vision "to be the center of the communities we serve" and are home to a diverse mix of thriving national, regional and local retailers. Brixmor is a proud real estate partner to over 5,000 retailers including The TJX Companies, The Kroger Co., Publix Super Markets and Ross Stores.

Brixmor Property Group Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moleculin Biotech (MBRX), Addus Homecare (ADUS) and ...

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX), Addus Homecare (ADUS) and Rhythm Pharmaceuticals (RYTM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moleculin Biotech (MBRX), Merit Medical Systems (MMSI) and Modern...

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX), Merit Medical Systems (MMSI) and Moderna (MRNA)

ImmunityBio ( ($IBRX) ) has shared an announcement. On July 29, 2026, ImmunityBio announced that the Emirates Drug Establishment of the United Arab...

ImmunityBio wins UAE approval for ANKTIVA cancer therapies

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on NETSTREIT (NTST), UDR (UDR) and Brixmor Property ...

Analysts Offer Insights on Real Estate Companies: NETSTREIT (NTST), UDR (UDR) and Brixmor Property (BRX)

Piper Sandler analyst Alexander Goldfarb maintained a Buy rating on Brixmor Property today and set a price target of $40.00. According to TipRanks,...

Piper Sandler Sticks to Their Buy Rating for Brixmor Property (BRX)

In a report released today, Juan C. Sanabria from BMO Capital reiterated a Buy rating on Brixmor Property, with a price target of $37.00. C. Sanabr...

BMO Capital Keeps Their Buy Rating on Brixmor Property (BRX)

Forte Biosciences received a Hold rating and a $77.00 price target from Evercore ISI analyst Gavin Clark-Gartner today. According to TipRanks, Clar...

Forte Biosciences (FBRX) was downgraded to a Hold Rating at Evercore ISI

LB Pharmaceuticals, Inc. ( ($LBRX) ) just unveiled an announcement. On July 22, 2026, LB Pharmaceuticals announced that faster-than-expected enroll...

LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline

Goldman Sachs analyst Caitlin Burrows maintained a Buy rating on Brixmor Property yesterday and set a price target of $35.00. The company’s shares ...

Brixmor Property (BRX) Receives a Buy from Goldman Sachs

Belararox Ltd. ( ($AU:BRX) ) has shared an announcement. Belararox has refined interpretation of airborne electromagnetic data over key tenements a...

Belararox sharpens Kalahari copper targets as it rebrands to Vantage Metals

Belararox Ltd. ( ($AU:BRX) ) has issued an announcement. Belararox Limited has secured shareholder approval to change its corporate name to Vantage...

Belararox Rebrands as Vantage Metals, Changes ASX Code to VAN

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT...

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

Belararox Ltd. ( ($AU:BRX) ) has issued an update. Belararox shareholders endorsed all resolutions put to a general meeting held on 10 July 2026, w...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BRX	$30.37	+0.73%	2.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BRX	$30.37	+0.7%	2.66M
3
4
5
6

BRX

BRX

Get Brixmor Property Group Inc. Data in Excel

Get Brixmor Property Group Inc. Data in Excel